|Positive IHC detected in||human prostate cancer tissue, human ovary tumor tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Immunohistochemistry (IHC)||IHC : 1:500-1:2000|
|Sample-dependent, check data in validation data gallery|
The immunogen of 20305-1-AP is CD47 Fusion Protein expressed in E. coli.
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||CD47 fusion protein Ag14132|
|Full Name||CD47 molecule|
|Calculated molecular weight||323 aa, 35 kDa|
|Observed molecular weight||47-55 kDa|
|GenBank accession number||BC010016|
|Gene ID (NCBI)||961|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
CD47, also known as integrin-associated protein (IAP), is a member of the immunoglobulin superfamily containing a five-pass transmembrane attachment. CD47 is heavily glycosylated and widely expressed by hematopoietic and nonhematopoietic cells. CD47 interacts with several membrane integrins and also acts a receptor for thrombospondin (THBS1). It is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. CD47 also functions as a ligand for signal regulatory protein-α (SIRPα). Upon binding CD47, SIRPα initiates a signaling cascade that results in the inhibition of phagocytosis.
Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.
J Cancer Res Clin Oncol
Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.
J Cell Commun Signal
CD47 interactions with exportin-1 limit the targeting of m 7 G-modified RNAs to extracellular vesicles
Front Cell Dev Biol
Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis.
ACS Appl Mater Interfaces
Bioengineering CXCR4-overexpressing cell membrane functionalized ROS-responsive nanotherapeutics for targeting cerebral ischemia-reperfusion injury.